436 related articles for article (PubMed ID: 26327754)
1. Management of hepatitis delta: Need for novel therapeutic options.
Abbas Z; Abbas M
World J Gastroenterol; 2015 Aug; 21(32):9461-5. PubMed ID: 26327754
[TBL] [Abstract][Full Text] [Related]
2. Strategies to inhibit entry of HBV and HDV into hepatocytes.
Urban S; Bartenschlager R; Kubitz R; Zoulim F
Gastroenterology; 2014 Jul; 147(1):48-64. PubMed ID: 24768844
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis D Virus Infection of Mice Expressing Human Sodium Taurocholate Co-transporting Polypeptide.
He W; Ren B; Mao F; Jing Z; Li Y; Liu Y; Peng B; Yan H; Qi Y; Sun Y; Guo JT; Sui J; Wang F; Li W
PLoS Pathog; 2015 Apr; 11(4):e1004840. PubMed ID: 25902143
[TBL] [Abstract][Full Text] [Related]
4. Viral entry of hepatitis B and D viruses and bile salts transportation share common molecular determinants on sodium taurocholate cotransporting polypeptide.
Yan H; Peng B; Liu Y; Xu G; He W; Ren B; Jing Z; Sui J; Li W
J Virol; 2014 Mar; 88(6):3273-84. PubMed ID: 24390325
[TBL] [Abstract][Full Text] [Related]
5. Treatment of delta hepatitis.
Gunsar F
Expert Rev Anti Infect Ther; 2013 May; 11(5):489-98. PubMed ID: 23627855
[TBL] [Abstract][Full Text] [Related]
6. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.
Nkongolo S; Ni Y; Lempp FA; Kaufman C; Lindner T; Esser-Nobis K; Lohmann V; Mier W; Mehrle S; Urban S
J Hepatol; 2014 Apr; 60(4):723-31. PubMed ID: 24295872
[TBL] [Abstract][Full Text] [Related]
7. In vivo antiviral efficacy of prenylation inhibitors against hepatitis delta virus.
Bordier BB; Ohkanda J; Liu P; Lee SY; Salazar FH; Marion PL; Ohashi K; Meuse L; Kay MA; Casey JL; Sebti SM; Hamilton AD; Glenn JS
J Clin Invest; 2003 Aug; 112(3):407-14. PubMed ID: 12897208
[TBL] [Abstract][Full Text] [Related]
8. A screening assay for the identification of host cell requirements and antiviral targets for hepatitis D virus infection.
Buchmann B; Döhner K; Schirdewahn T; Sodeik B; Manns MP; Wedemeyer H; Ciesek S; von Hahn T
Antiviral Res; 2017 May; 141():116-123. PubMed ID: 28223128
[TBL] [Abstract][Full Text] [Related]
9. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.
Bogomolov P; Alexandrov A; Voronkova N; Macievich M; Kokina K; Petrachenkova M; Lehr T; Lempp FA; Wedemeyer H; Haag M; Schwab M; Haefeli WE; Blank A; Urban S
J Hepatol; 2016 Sep; 65(3):490-8. PubMed ID: 27132170
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes.
Ni Y; Lempp FA; Mehrle S; Nkongolo S; Kaufman C; Fälth M; Stindt J; Königer C; Nassal M; Kubitz R; Sültmann H; Urban S
Gastroenterology; 2014 Apr; 146(4):1070-83. PubMed ID: 24361467
[TBL] [Abstract][Full Text] [Related]
11. Future treatments for hepatitis delta virus infection.
Asselah T; Loureiro D; Tout I; Castelnau C; Boyer N; Marcellin P; Mansouri A
Liver Int; 2020 Feb; 40 Suppl 1():54-60. PubMed ID: 32077603
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis D virus infection, innate immune response and antiviral treatments in stem cell-derived hepatocytes.
Lange F; Garn J; Anagho HA; Vondran FWR; von Hahn T; Pietschmann T; Carpentier A
Liver Int; 2023 Oct; 43(10):2116-2129. PubMed ID: 37366005
[TBL] [Abstract][Full Text] [Related]
13. Prenylation of HDAg and antiviral drug development.
Glenn JS
Curr Top Microbiol Immunol; 2006; 307():133-49. PubMed ID: 16903224
[TBL] [Abstract][Full Text] [Related]
14. Primary biliary acids inhibit hepatitis D virus (HDV) entry into human hepatoma cells expressing the sodium-taurocholate cotransporting polypeptide (NTCP).
Veloso Alves Pereira I; Buchmann B; Sandmann L; Sprinzl K; Schlaphoff V; Döhner K; Vondran F; Sarrazin C; Manns MP; Pinto Marques Souza de Oliveira C; Sodeik B; Ciesek S; von Hahn T
PLoS One; 2015; 10(2):e0117152. PubMed ID: 25646622
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis D revival.
Wedemeyer H
Liver Int; 2011 Jan; 31 Suppl 1():140-4. PubMed ID: 21205152
[TBL] [Abstract][Full Text] [Related]
16. Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle.
Blanchet M; Sureau C; Labonté P
Antiviral Res; 2014 Jun; 106():111-5. PubMed ID: 24717262
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of in vivo hepatitis D virus infection.
Goyal A; Murray JM
J Theor Biol; 2016 Jun; 398():9-19. PubMed ID: 27012516
[TBL] [Abstract][Full Text] [Related]
18. Targeting Hepatitis D.
Rizzetto M
Semin Liver Dis; 2018 Feb; 38(1):66-72. PubMed ID: 29471567
[TBL] [Abstract][Full Text] [Related]
19. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.
Lütgehetmann M; Mancke LV; Volz T; Helbig M; Allweiss L; Bornscheuer T; Pollok JM; Lohse AW; Petersen J; Urban S; Dandri M
Hepatology; 2012 Mar; 55(3):685-94. PubMed ID: 22031488
[TBL] [Abstract][Full Text] [Related]
20. A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide.
Kaneko M; Watashi K; Kamisuki S; Matsunaga H; Iwamoto M; Kawai F; Ohashi H; Tsukuda S; Shimura S; Suzuki R; Aizaki H; Sugiyama M; Park SY; Ito T; Ohtani N; Sugawara F; Tanaka Y; Mizokami M; Sureau C; Wakita T
J Virol; 2015 Dec; 89(23):11945-53. PubMed ID: 26378168
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
